The Venture Codex

Participated · Equity · Jun 2023

NVision Imaging develops MRI polarizers and hyperpolarized imaging agents that enable metabolic MRI. Its NVision Polarizer uses a parahydrogen-induced polarization (PHIP) technique, applying advances in quantum physics, chemistry, and engineering to deliver fast, robust, and easy-to-use polarization in the MRI setting. The technology aims to detect early metabolic changes at the cellular level, potentially revealing treatment response within days rather than months. NVision planned preclinical use in 2023 and intends to deploy systems for human care in the coming years, targeting installations at over 50 leading cancer centers by 2025. The company has a partnership with Siemens Healthineers and a signed collaboration with Memorial Sloan Kettering to support clinical deployment. Financially, NVision closed a $30M Series A and secured additional government funding to support its clinical advancement.

Participated · Grant · Jun 2023

delphai is a B2B AI data provider that builds an API-first firmographic intelligence platform aggregating tens of millions of businesses and over 20 billion data points. Its product ingests millions of websites, press releases, job postings and other sources weekly to create a near-real-time, highly accurate single source of company truth accessible via dashboard, API or integrations. The company uses frontier natural language processing systems to automate and trace data acquisition, differentiating itself from competitors who rely on government registries, simple web scrapers, or human click workers. delphai serves data teams, global consultancies, M&A departments, and digital sales/CRM teams, counting three of the four largest global consultancies among its clients. In 2022 it reported over 100% growth in recurring revenue and a 5.5x increase in customers, with adoption driven by granular data, enhancement of stale data, and bespoke AI models. With the new funding, delphai plans to finance its AI models and scale processing to handle exponentially more data, positioning itself to lead the firmographic market as AI becomes a game-changer for Big Data.

Led · Grant · Apr 2017

Hemovent develops MOBYBOX, a self-contained, fully integrated ExtraCorporeal Membrane Oxygenation (ECMO/ECLS) system designed to support or replace heart and lung function. MOBYBOX is CE‑marked and approved for sale in Europe, but is not approved for distribution outside the European Union. The company positions MOBYBOX around ease of use, mobility and high performance as advantages versus standard of care. Hemovent describes itself as having a proprietary platform technology for heart- and lung-support and is pursuing a phased market introduction. The company plans post-market clinical follow-up (PMCF) studies in select clinical settings across Europe as part of its rollout. Recent financing activity is intended to accelerate the market introduction and clinical follow-up of MOBYBOX. Hemovent is an emerging medical device company based in Aachen, Germany, with a proprietary platform for heart and lung support. Its core product, the MOBYBOX™ System, is a self-contained, fully integrated ECMO/ECLS device designed for safety, ease of use, mobility, and performance to support or replace heart and lung function. Hemovent closed a $5.2 million Series B financing round to fund roll-out and regulatory activities. Management expects EU regulatory approval this year and says the funding provides sufficient resources to commence roll-out upon CE approval and to seek FDA clearance in due course. The company has been certified under ISO 13485:2016, which it describes as the next-to-last step in the CE marking process, and completed a GLP standardized in vivo 7-day study for long-term use. The MOBYBOX™ System is not yet approved for human use. Hemovent develops an Extra Corporeal Membrane Oxygenation (ECMO) system that the company describes as the world's smallest, fully portable device to support or replace heart or lung function. Because the devices are about one-tenth the size of similar technologies, they enable easier transport of patients from emergency sites or between hospitals. Hemovent says its systems also cost roughly half the price of comparable devices. The company reports positive in‑vivo experiments carried out since April. Management has stated it wants to bring the solution to market quickly and is seeking CE certification prior to commercial launch. Financially, Hemovent completed a €2 million expansion of a Series A that was €6 million in February 2016. Hemovent is a venture-backed medical device company developing novel, portable artificial lung technologies for applications ranging from Extracorporeal CO2 Removal to ExtraCorporeal Life Support. The company has developed small, self-contained fully portable artificial lungs intended for ECMO/ECLS to support or replace heart and lung function during cardiac and/or respiratory failure. Hemovent plans to use the grant funding to accelerate development of these portable artificial lung systems. The company is led by co-founder and CEO Christof Lenz and co-founder and CTO Oliver Marseille, Ph.D. Hemovent is based in Aachen, Germany and is backed by a group of investors. Its current financial news includes receipt of a government grant totaling $810k to support R&D efforts. Hemovent is an emerging medical device company based in Aachen, Germany, developing the world’s smallest, self-contained and fully portable Extra Corporeal Membrane Oxygenation (ECMO) system. The device is designed to reduce the footprint of ECMO therapy by about 90%, weighs roughly two pounds, and the company says it requires neither battery nor software. Hemovent describes the system as extremely robust and operating like a natural heart, intended to simplify patient transport and mobilization during treatment. Management and investors position the portable form factor as a way to broaden ECMO use by addressing current technology’s complexity, cost and lack of portability. The article states ECMO markets are growing rapidly and Hemovent aims to make ECMO deployment easier and more cost-effective. Hemovent closed a $6 million Series A to advance its product development and commercialization efforts.